Survivors | Non-survivors | P value | |
---|---|---|---|
(n = 970) | (n = 30) | ||
Demographics | |||
Age (yrs)* | 63 ± 7 | 68 ± 6 | <0.0001 |
Female gendera | 352 (36) | 11 (37) | 0.97 |
BMI (kg/m2)* | 26.8 ± 5.8 | 27.3 ± 7.8 | 0.78 |
Current smoker (%)a | 366 (38) | 3 (10) | 0.004 |
Pack years (yrs)* | 47 ± 25 | 56 ± 42 | 0.27 |
Clinical variables | |||
FEV1 (L)* | 1.42 ± 0.51 | 1.27 ± 0.43 | 0.11 |
FEV1 (% predicted)* | 51 ± 15 | 48 ± 13 | 0.44 |
GOLD Stageb | |||
II | 480 (49) | 14 (47) | 0.93 |
III | 392 (40) | 14 (47) | |
IV | 98 (10) | 2 (7) | |
Number of previous exacerbationsb | |||
0 | 531 (55) | 20 (67) | 0.29 |
1 | 239 (25) | 5 (17) | |
2 | 116 (12) | 2 (7) | |
> 2 | 84 (9) | 3 (10) | |
6MWD (meters)* | 386 ± 119 | 335 ± 105 | 0.02 |
mMRC dyspnoea score; median (Q1; Q3) b | 1 (1;2) | 2 (1;3) | 0.02 |
%LAA (%)* | 16.3 ± 11.3 | 17.4 ± 10.5 | 0.61 |
BODE index; median (Q1; Q3) b | 3 (1;4) | 3.5 (2;5) | 0.06 |
SGRQ total score* | 46 ± 18 | 50 ± 20 | 0.29 |
FACIT fatigue score* | 36 ± 10 | 31 ± 12 | 0.01 |
Comorbiditiesa | |||
Cardiovascular history | 304 (31) | 12 (40) | 0.42 |
Hypertension | 381 (39) | 14 (47) | 0.53 |
Asthma history | 225 (23) | 8 (27) | 0.82 |
Diabetes type II | 82 (8) | 3 (10) | 0.97 |
Osteoarthritis | 125 (13) | 3 (10) | 0.85 |
Osteoporosis | 121 (12) | 6 (20) | 0.35 |
Rheumatoid arthritis | 29 (3) | 0 (0) | 0.68 |
Inflammatory bowel disorder | 48 (5) | 1 (3) | 0.98 |
Interventionsa | |||
Inhaled corticosteroids | 140 (14) | 3 (10) | 0.68 |
Systemic corticosteroids | 8 (0.8) | 0 (0) | 0.59 |
Statins | 237 (24) | 6 (20) | 0.73 |